SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-000615
Filing Date
2024-02-01
Accepted
2024-02-01 17:28:10
Documents
15
Period of Report
2024-01-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 40496
  Complete submission text file 0001683168-24-000615.txt   259681

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE coep-20230129.xsd EX-101.SCH 3263
3 XBRL DEFINITION FILE coep-20230129_def.xml EX-101.DEF 26557
4 XBRL LABEL FILE coep-20230129_lab.xml EX-101.LAB 36481
5 XBRL PRESENTATION FILE coep-20230129_pre.xml EX-101.PRE 25181
16 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5499
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

IRS No.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 24588021
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)